VERTEX PHARMACEUTICALS INCORPORATED
Last · NASDAQ$498.50+13.28 (+2.74%)close · yahoo · 14h ago
Market cap$126.27B253.3M sh
P/E · TTM29.0fwd 24.8 · eps 17.17
Beta0.28vs S&P 500
Div yield0.00%annual · TTM
52w range
$403.16$560.25
Volume2.1Msession
| Revenue | $12.6B |
|---|---|
| Operating income | $4.8B |
| Net income | $4.4B |
| Free cash flow | $3.8B |
| Operating margin | 38.0% |
| Net margin | 35.0% |
| Return on equity | 21.8% |
| Period | TTM 2026-06-30 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-02-13
- Cf Revenue Concentration
- Journavx Launch
- Casgevy Adoption
- Pipeline Investment
- Pricing Reimbursement
- Gene Editing Manufacturing
Red flags
- Substantially all net product revenue has historically come from CF medicines, creating concentration risk around manufacturing or supply disruption, safety findings, competition, and pricing pressure.
- CASGEVY revenue was only $115.8 million in 2025 despite approval across multiple geographies; adoption remains constrained by complex manufacturing and administration requirements.
- Total R&D and SG&A reached $5.7 billion in 2025, up from $5.1 billion, while 2026 development and commercial expenses are expected to increase further.
- Pricing and reimbursement risk is concrete: TRIKAFTA was selected for a Colorado affordability review, and Vertex faces broader government and payer pressure on access and drug pricing.
Upcoming earnings
9:00 PM UTC+1
Period
Sep 2026
Est. EPS
$0.04
Est. revenue
3.4B